These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong. Chang KC; Leung EC; Law WS; Leung WM; Tai LB; Lee SN; Lam FM; Chau CH; Mok TY; Yew WW; Leung CC Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29650556 [No Abstract] [Full Text] [Related]
8. [New antitubercular agents are not where where we need them to be]. Nau JY Rev Med Suisse; 2015 Dec; 11(499):2408-9. PubMed ID: 26852561 [No Abstract] [Full Text] [Related]
9. India plans to expand access to new tuberculosis drug. Sharma DC Lancet; 2017 Feb; 389(10070):685. PubMed ID: 28229866 [No Abstract] [Full Text] [Related]
10. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862 [No Abstract] [Full Text] [Related]
11. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens. Kuksa L; Barkane L; Hittel N; Gupta R Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917 [No Abstract] [Full Text] [Related]
12. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis. Hafkin J; Hittel N; Martin A; Gupta R Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253 [No Abstract] [Full Text] [Related]
13. [Tuberculosis: new treatment options and updated recommendations]. Schaberg T Dtsch Med Wochenschr; 2013 Apr; 138(14):725-7. PubMed ID: 23533039 [No Abstract] [Full Text] [Related]
14. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis. Thakare R; Soni I; Dasgupta A; Chopra S Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067 [TBL] [Abstract][Full Text] [Related]
16. The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis. Halleux CM; Falzon D; Merle C; Jaramillo E; Mirzayev F; Olliaro P; Weyer K Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29567719 [No Abstract] [Full Text] [Related]
17. Drug-resistance mechanisms and tuberculosis drugs. Köser CU; Javid B; Liddell K; Ellington MJ; Feuerriegel S; Niemann S; Brown NM; Burman WJ; Abubakar I; Ismail NA; Moore D; Peacock SJ; Török ME Lancet; 2015 Jan; 385(9965):305-7. PubMed ID: 25706840 [No Abstract] [Full Text] [Related]
18. Barriers to new drug development in respiratory disease. Brigden G; du Cros P; Wong S Eur Respir J; 2016 Jan; 47(1):356-7. PubMed ID: 26721975 [No Abstract] [Full Text] [Related]
19. The STREAM trial: missed opportunities and lessons for future clinical trials. Loveday M; Reuter A; Furin J; Seddon JA; Cox H Lancet Infect Dis; 2019 Apr; 19(4):351-353. PubMed ID: 30910428 [No Abstract] [Full Text] [Related]